You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Life & Medical Care

Global Hormone Refractory Breast Cancer Market Report, History and Forecast 2015-2026, Breakdown Data by Companies, Key Regions, Types and Application

An increasing number of hormone therapies have made refractory breast cancer resistant to treatment, increased incidence of breast cancer, aging population, increased demand for advanced therapies, increased incidence of hormone-refractory breast cancer and the existence of a large number of anti-cancer pipeline drugs, all of which drive the growth of hormone-refractory breast cancer market.
Market Analysis and Insights: Global Hormone Refractory Breast Cancer Market
The global Hormone Refractory Breast Cancer market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Hormone Refractory Breast Cancer Scope and Segment
The global Hormone Refractory Breast Cancer market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Hormone Refractory Breast Cancer market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.
The major regions covered in the report are North America, Europe, China, Rest of Asia Pacific, Central & South America, Middle East & Africa, etc. It includes revenue analysis of each region for the year 2015 to 2026.
By the type, the market is primarily split into
Tumor Markers Therapy
Gene Expression Therapy
Gene Mutation Therapy
By the application, this report covers the following segments
Scientific Research and Production
Biological Science and Technology
Medical Technology
Medical Apparatus and Instruments
Competitive Landscape:
The Hormone Refractory Breast Cancer key manufacturers in this market include:
AstraZeneca
AmpliMed Corporation
Roche
Bluefish Pharmaceuticals AB
NeoCorp
Sanofi Genzyme
Neopharm
Boehringer Ingelheim GmbH
1 Market Overview of Hormone Refractory Breast Cancer
1.1 Hormone Refractory Breast Cancer Market Overview
1.1.1 Hormone Refractory Breast Cancer Product Scope
1.1.2 Market Status and Outlook
1.2 Global Hormone Refractory Breast Cancer Market Size Overview by Region 2015 VS 2020 VS 2026
1.3 Global Hormone Refractory Breast Cancer Market Size by Region (2015-2026)
1.4 Global Hormone Refractory Breast Cancer Historic Market Size by Region (2015-2020)
1.5 Global Hormone Refractory Breast Cancer Market Size Forecast by Region (2021-2026)
1.6 Key Regions, Hormone Refractory Breast Cancer Market Size YoY Growth (2015-2026)
1.6.1 North America Hormone Refractory Breast Cancer Market Size YoY Growth (2015-2026)
1.6.2 Europe Hormone Refractory Breast Cancer Market Size YoY Growth (2015-2026)
1.6.3 China Hormone Refractory Breast Cancer Market Size YoY Growth (2015-2026)
1.6.4 Rest of Asia Pacific Hormone Refractory Breast Cancer Market Size YoY Growth (2015-2026)
1.6.5 Latin America Hormone Refractory Breast Cancer Market Size YoY Growth (2015-2026)
1.6.6 Middle East & Africa Hormone Refractory Breast Cancer Market Size YoY Growth (2015-2026)

2 Hormone Refractory Breast Cancer Market Overview by Type
2.1 Global Hormone Refractory Breast Cancer Market Size by Type: 2015 VS 2020 VS 2026
2.2 Global Hormone Refractory Breast Cancer Historic Market Size by Type (2015-2020)
2.3 Global Hormone Refractory Breast Cancer Forecasted Market Size by Type (2021-2026)
2.4 Tumor Markers Therapy
2.5 Gene Expression Therapy
2.6 Gene Mutation Therapy

3 Hormone Refractory Breast Cancer Market Overview by Application
3.1 Global Hormone Refractory Breast Cancer Market Size by Application: 2015 VS 2020 VS 2026
3.2 Global Hormone Refractory Breast Cancer Historic Market Size by Application (2015-2020)
3.3 Global Hormone Refractory Breast Cancer Forecasted Market Size by Application (2021-2026)
3.4 Scientific Research and Production
3.5 Biological Science and Technology
3.6 Medical Technology
3.7 Medical Apparatus and Instruments

4 Global Hormone Refractory Breast Cancer Competition Analysis by Players
4.1 Global Hormone Refractory Breast Cancer Market Size (Million US$) by Players (2015-2020)
4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hormone Refractory Breast Cancer as of 2019)
4.3 Date of Key Manufacturers Enter into Hormone Refractory Breast Cancer Market
4.4 Global Top Players Hormone Refractory Breast Cancer Headquarters and Area Served
4.5 Key Players Hormone Refractory Breast Cancer Product Solution and Service
4.6 Competitive Status
4.6.1 Hormone Refractory Breast Cancer Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans

5 Company (Top Players) Profiles and Key Data
5.1 AstraZeneca
5.1.1 AstraZeneca Profile
5.1.2 AstraZeneca Main Business and Company’s Total Revenue
5.1.3 AstraZeneca Products, Services and Solutions
5.1.4 AstraZeneca Revenue (US$ Million) (2015-2020)
5.1.5 AstraZeneca Recent Development and Reaction to Covid-19
5.2 AmpliMed Corporation
5.2.1 AmpliMed Corporation Profile
5.2.2 AmpliMed Corporation Main Business and Company’s Total Revenue
5.2.3 AmpliMed Corporation Products, Services and Solutions
5.2.4 AmpliMed Corporation Revenue (US$ Million) (2015-2020)
5.2.5 AmpliMed Corporation Recent Development and Reaction to Covid-19
5.3 Roche
5.5.1 Roche Profile
5.3.2 Roche Main Business and Company’s Total Revenue
5.3.3 Roche Products, Services and Solutions
5.3.4 Roche Revenue (US$ Million) (2015-2020)
5.3.5 Bluefish Pharmaceuticals AB Recent Development and Reaction to Covid-19
5.4 Bluefish Pharmaceuticals AB
5.4.1 Bluefish Pharmaceuticals AB Profile
5.4.2 Bluefish Pharmaceuticals AB Main Business and Company’s Total Revenue
5.4.3 Bluefish Pharmaceuticals AB Products, Services and Solutions
5.4.4 Bluefish Pharmaceuticals AB Revenue (US$ Million) (2015-2020)
5.4.5 Bluefish Pharmaceuticals AB Recent Development and Reaction to Covid-19
5.5 NeoCorp
5.5.1 NeoCorp Profile
5.5.2 NeoCorp Main Business and Company’s Total Revenue
5.5.3 NeoCorp Products, Services and Solutions
5.5.4 NeoCorp Revenue (US$ Million) (2015-2020)
5.5.5 NeoCorp Recent Development and Reaction to Covid-19
5.6 Sanofi Genzyme
5.6.1 Sanofi Genzyme Profile
5.6.2 Sanofi Genzyme Main Business and Company’s Total Revenue
5.6.3 Sanofi Genzyme Products, Services and Solutions
5.6.4 Sanofi Genzyme Revenue (US$ Million) (2015-2020)
5.6.5 Sanofi Genzyme Recent Development and Reaction to Covid-19
5.7 Neopharm
5.7.1 Neopharm Profile
5.7.2 Neopharm Main Business and Company’s Total Revenue
5.7.3 Neopharm Products, Services and Solutions
5.7.4 Neopharm Revenue (US$ Million) (2015-2020)
5.7.5 Neopharm Recent Development and Reaction to Covid-19
5.8 Boehringer Ingelheim GmbH
5.8.1 Boehringer Ingelheim GmbH Profile
5.8.2 Boehringer Ingelheim GmbH Main Business and Company’s Total Revenue
5.8.3 Boehringer Ingelheim GmbH Products, Services and Solutions
5.8.4 Boehringer Ingelheim GmbH Revenue (US$ Million) (2015-2020)
5.8.5 Boehringer Ingelheim GmbH Recent Development and Reaction to Covid-19

6 North America Hormone Refractory Breast Cancer by Players and by Application
6.1 North America Hormone Refractory Breast Cancer Market Size and Market Share by Players (2015-2020)
6.2 North America Hormone Refractory Breast Cancer Market Size by Application (2015-2020)

7 Europe Hormone Refractory Breast Cancer by Players and by Application
7.1 Europe Hormone Refractory Breast Cancer Market Size and Market Share by Players (2015-2020)
7.2 Europe Hormone Refractory Breast Cancer Market Size by Application (2015-2020)

8 China Hormone Refractory Breast Cancer by Players and by Application
8.1 China Hormone Refractory Breast Cancer Market Size and Market Share by Players (2015-2020)
8.2 China Hormone Refractory Breast Cancer Market Size by Application (2015-2020)

9 Rest of Asia Pacific Hormone Refractory Breast Cancer by Players and by Application
9.1 Rest of Asia Pacific Hormone Refractory Breast Cancer Market Size and Market Share by Players (2015-2020)
9.2 Rest of Asia Pacific Hormone Refractory Breast Cancer Market Size by Application (2015-2020)

10 Latin America Hormone Refractory Breast Cancer by Players and by Application
10.1 Latin America Hormone Refractory Breast Cancer Market Size and Market Share by Players (2015-2020)
10.2 Latin America Hormone Refractory Breast Cancer Market Size by Application (2015-2020)

11 Middle East & Africa Hormone Refractory Breast Cancer by Players and by Application
11.1 Middle East & Africa Hormone Refractory Breast Cancer Market Size and Market Share by Players (2015-2020)
11.2 Middle East & Africa Hormone Refractory Breast Cancer Market Size by Application (2015-2020)

12 Hormone Refractory Breast Cancer Market Dynamics
12.1 Covid-19 Impact: Industry Trends
12.2 Covid-19 Impact: Market Drivers
12.3 Covid-19 Impact: Market Challenges
12.4 Porter’s Five Forces Analysis

13 Research Finding /Conclusion

14 Methodology and Data Source
14.1 Methodology/Research Approach
14.1.1 Research Programs/Design
14.1.2 Market Size Estimation
14.1.3 Market Breakdown and Data Triangulation
14.2 Data Source
14.2.1 Secondary Sources
14.2.2 Primary Sources
14.3 Disclaimer
14.4 Author List
  • FORMAT: PDF
  • PUBLISHED DATE: Nov, 2020
  • NO OF PAGES: 125